Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.59 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477096 | 0.90 | MAPKAPK5 (0.74) | MAPKAPK5PTK6JAK2AURKBLCK | |
| SCHEMBL12443314 | 0.89 | MAPKAPK5 (0.57) | MAPKAPK5PTK6TLR9TLR8TLR7 | |
| SCHEMBL1475895 | 0.87 | MAPKAPK5 (0.61) | MAPKAPK5PTK6TLR9TLR8TLR7 | |
| SCHEMBL1475806 | 0.86 | MAPKAPK5 (0.59) | MAPKAPK5PTK6TLR9TLR8TLR7 | |
| SCHEMBL12443304 | 0.86 | MAPKAPK5 (0.65) | MAPKAPK5PTK6JAK2SYKAURKB | |
| SCHEMBL12443302 | 0.86 | MAPKAPK5 (0.67) | MAPKAPK5PTK6JAK2SYKAURKB | |
| SCHEMBL13445129 | 0.85 | MAPKAPK5 (0.66) | MAPKAPK5PTK6AURKBLCKROCK2 | |
| SCHEMBL1476426 | 0.85 | MAPKAPK5 (0.80) | MAPKAPK5PTK6AURKBLCKFLT3 | |
| SCHEMBL10169172 | 0.85 | MAPKAPK5 (0.58) | MAPKAPK5PTK6AURKBLCKAURKA | |
| SCHEMBL1476474 | 0.83 | MAPKAPK5 (0.61) | MAPKAPK5PTK6TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | claimed |
| EP-2029602-B1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-04-21 | — | — | EP | claimed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | claimed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | claimed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | MAPKAPK5 5/4885PTK6 1486/4885TLR9 3054/4885 |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PTK6 1659/4885TLR9 2199/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PTK6 1659/4885TLR9 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.